What FDA clearance means for Median Technologies eyonis LCS in a crowded AI radiology market
Median Technologies advances eyonis LCS after FDA clearance. Discover what this means for AI lung cancer screening and European expansion.
Lucent Diagnostics expands cognitive biomarker reach through Life Line Screening
Lucent Diagnostics partners with Life Line Screening to expand Alzheimer’s blood testing nationwide. Discover what this means for early detection.
Faster Candida auris identification? Thermo Fisher Scientific unveils new agar
Thermo Fisher Scientific launches chromogenic media to detect Candida auris faster. Explore what this means for labs and AMR strategy.
New HSS data question bleeding risks of NSAIDs in anticoagulated hip replacement patients
New HSS data challenge assumptions on aspirin, NSAIDs, and cefazolin in joint replacement. See what this means for bleeding, pain, and infection risk.
Can Acadia overturn EMA’s negative opinion on trofinetide for Rett syndrome?
Acadia seeks EU re-examination after CHMP rejects trofinetide for Rett syndrome. Read the regulatory and clinical implications.
Ono Pharmaceutical strengthens early-stage pipeline with Congruence platform deal
Ono Pharmaceutical expands its Congruence alliance into neurology and immunology. Explore what this means for AI-driven drug discovery and pipeline risk.
Meiji Seika Pharma wins EU orphan drug status for morcamilast in palmoplantar pustulosis
EU orphan status for morcamilast in PPP reshapes Meiji Seika Pharma’s European strategy. See what it means for PDE4 competition and rare dermatology.
LRS wins FDA clearance to test ThermoSuit cooling device in pivotal ischemic stroke trial
Life Recovery Systems (LRS), a medical device developer headquartered in Alexandria, Louisiana, has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration to advance its ThermoSuit System into a pivotal clinical trial enrolling ischemic stroke patients. The study, which will enroll up to 160 patients across as many as eight hospitals, […]
Merck strengthens its women’s oncology position with KEYNOTE-B96 overall survival results
KEYNOTE-B96 shows overall survival gains for pembrolizumab in platinum-resistant ovarian cancer. Find out why this trial could reshape treatment strategy.
Can ctDNA-guided bladder preservation become viable after Signatera’s ASCO GU data?
New ASCO GU data shows how Signatera ctDNA may guide bladder preservation and adjuvant therapy decisions in muscle-invasive bladder cancer. Read the analysis.